Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor–armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous deletions spanning the CD19 locus and de novo f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Sotillo, Elena, Barrett, David M., Black, Kathryn L, Bagashev, Asen, Oldridge, Derek, Wu, Glendon, Sussman, Robyn, Lanauze, Claudia, Ruella, Marco, Gazzara, Matthew R., Martinez, Nicole M., Harrington, Colleen T., Chung, Elaine Y., Perazzelli, Jessica, Hofmann, Ted J., Maude, Shannon L., Raman, Pichai, Barrera, Alejandro, Gill, Saar, Lacey, Simon F., Melenhorst, Jan J., Allman, David, Jacoby, Elad, Fry, Terry, Mackall, Crystal, Barash, Yoseph, Lynch, Kristen W., Maris, John M., Grupp, Stephan A., Thomas-Tikhonenko, Andrei
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670800/
https://ncbi.nlm.nih.gov/pubmed/26516065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados